Advanced oxidation protein products induce apoptosis, and upregulate sclerostin and RANKL expression, in osteocytic MLO-Y4 cells via JNK/p38 MAPK activation

Molecular Medicine Reports

Volumn 15, Issue 2, 2017, Pages 543-550

  Yu, Chaoqun ^a   Huang, Dong ^a   Wang, Kunyuan ^a   Lin, Bochuan ^a   Liu, Yuanhang ^a   Liu, Songbo ^a   Wu, Weichi ^a   Zhang, Huiru ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Advanced oxidation protein products; Apoptosis; Mitogen activated protein kinases; Osteocyte; RANKL; Reactive oxygen species; Sclerostin

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; ADVANCED OXIDATION PROTEIN PRODUCT; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; APOCYNIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; REACTIVE OXYGEN METABOLITE; SCLEROSTIN; STRESS ACTIVATED PROTEIN KINASE; ANTHRACENE DERIVATIVE; GLYCOPROTEIN; IMIDAZOLE DERIVATIVE; PYRAZOLANTHRONE; PYRIDINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SOST PROTEIN, MOUSE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE REMODELING; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOLYSIS; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; GENETICS; METABOLISM; SIGNAL TRANSDUCTION;

ACETYLCYSTEINE; ADVANCED OXIDATION PROTEIN PRODUCTS; ANIMALS; ANTHRACENES; APOPTOSIS; CELL LINE; GLYCOPROTEINS; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; NADPH OXIDASE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RANK LIGAND; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 85009121784     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.6047     Document Type: Article

References (31)

1. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Zingraff J, Jungers P and Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304-1313, 1996.
2. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drüeke T and Descamps-Latscha B: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure1,2. J Immunol 161: 2524-2532, 1998
3. Tucker PS, Dalbo VJ, Han T and Kingsley MI: Clinical and research markers of oxidative stress in chronic kidney disease. Biomarkers 18: 103-115, 2013.
4. Krzystek-Korpacka M, Neubauer K, Berdowska I, Boehm D, Zielinski B, Petryszyn P, Terlecki G, Paradowski L and Gamian A: Enhanced formation of advanced oxidation protein products in IBD. Inflamm Bowel Dis 14: 794-802, 2008.
5. Baskol G, Demir H, Baskol M, Kilic E, Ates F, Karakukcu C and Ustdal M: Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis. Cell Biochem Funct 24: 307-311, 2006.
6. Piwowar A, Knapik-Kordecka M and Warwas M: AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Res Clin Pract 77: 188-192, 2007.
7. Painter SE, Kleerekoper M and Camacho PM: Secondary osteoporosis: A review of the recent evidence. Endocr Pract 12: 436-445, 2006.
8. Zhong ZM, Bai L and Chen JT: Advanced oxidation protein products inhibit proliferation and differentiation of rat osteoblast-like cells via NF-kappaB pathway. Cell Physol Biochem 24: 105-114, 2009.
9. Sun N, Yang L, Li Y, Zhang H, Chen H, Liu D, Li Q and Cai D: Effect of advanced oxidation protein products on the proliferation and osteogenic differentiation of rat mesenchymal stem cells. Int J Mol Med 32: 485-491, 2013.
10. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 3597-3602, 1998.
11. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, et al: Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17: 1231-1234, 2011.
12. Semenov M, Tamai K and Xi H: SOST is a ligand for LRP5/LRP6 and a wnt signaling inhibitor. J Biol Chem 280: 26770-26775, 2005.
13. Krause C, Korchynskyi O, de Rooij K, Weidauer SE, de Gorter DJ, van Bezooijen RL, Hatsell S, Economides AN, Mueller TD, Löwik CW and ten Dijke P: Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 285: 41614-41626, 2010.
14. Kyriakis JM and Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869, 2001.
15. Reddy KB, Nabha SM and Atanaskova N: Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22: 395-403, 2003.
16. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-CT method. Methods 25: 402-408, 2001.
17. Burotto M, Chiou VL, Lee JM and Kohn EC: The MAPK pathway across different malignancies: A new perspective. Cancer 120: 3446-3456, 2014.
18. Thouverey C and Caverzasio J: Focus on the p38 MAPK signaling pathway in bone development and maintenance. Bonekey Rep 4: 711, 2015.
19. Wang SS, Huang QT, Zhong M and Yin Q: AOPPs (advanced oxidation protein products) promote apoptosis in trophoblastic cells through interference with NADPH oxidase signaling: Implications for preeclampsia. J Matern Fetal Neonatal Med 28: 1747-1755, 2015.
20. Zhou LL, Cao W, Xie C, Tian J, Zhou Z, Zhou Q, Zhu P, Li A, Liu Y, Miyata T, et al: The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int 82: 759-770, 2012.
21. Xie F, Sun S, Xu A, Zheng S, Xue M, Wu P, Zeng JH and Bai L: Advanced oxidation protein products induce intestine epithelial cell death through a redox-dependent, c-jun N-terminal kinase and poly (ADP-ribose) polymerase-1-mediated pathway. Cell Death Dis 5: e1006, 2014.
22. Bonewald LF: The amazing osteocyte. J Bone Res 26: 229-238, 2011.
23. Compton JT and Lee FY: A review of osteocyte function and the emerging importance of sclerostin. J Bone Joint Surg Am 96: 1659-1668, 2014.
24. Seibel MJ, Cooper MS and Zhou H: Glucocorticoid-induced osteoporosis: Mechanisms, management and future perspectives. Lancet Diabetes Endocrinol 1: 59-70, 2013.
25. Osone S, Hosoi H, Kuwahara Y, Matsumoto Y, Iehara T and Sugimoto T: Fenretinide induces sustained-activation of JNK/p38 MAPK and apoptosis in a reactive oxygen species-dependent manner in neuroblastoma cells. Int J Cancer 112: 219-224, 2004.
26. Park GB, Choi Y, Kim YS, Lee HK, Kim D and Hur DY: ROS-mediated JNK/p38-MAPK activation regulates bax translocation in sorafenib-induced apoptosis of EBV-transformed B cells. Int J Oncol 44: 977-985, 2014.
27. Lee SY, Kang SU, Kim KI, Kang S, Shin YS, Chang JW, Yang SS, Lee K, Lee JS, Moon E and Kim CH: Nonthermal plasma induces apoptosis in ATC cells: Involvement of JNK and p38 MAPK-dependent ROS. Yonsei Med J 55: 1640-1647, 2014.
28. Palit S, Kar S, Sharma G and Das PK: Hesperetin induces apoptosis in breast carcinoma by triggering accumulation of Ros and activation of ASK1/JNK Pathway. J Cell Physiol 230: 1729-1739, 2015.
29. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, et al: Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22: 6267-6276, 2003.
30. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM and Atkins GJ: Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PloS one 6: e25900, 2011.
31. Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I and Ominsky MS: Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 49: 151-161, 2011.